Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 6

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 6
---
 on the Nasdaq Capital Market under the symbol “BIAFW”. On April 25, 2025, the last reported sale price of (i) our Common Stock on Nasdaq was $0.499 per share, and (ii) our Tradeable Warrants on Nasdaq was $0.227 per Tradeable Warrant. There is no established public trading market for the May 2025 Warrants or the Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to apply for listing of the May 2025 Warrants or the Pre-Funded Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the May 2025 Warrants and the Pre-Funded Warrants will be limited.

Certain information in this prospectus is based on an assumed public offering price of $0.499 per Share and accompanying May 2025 Warrant (the last reported sale price of our Common Stock on Nasdaq on April 25, 2025). The actual public offering price will be determined between us and the Placement Agent based on market conditions at the time of pricing, and may be at a discount to the current market price of our Common Stock. Therefore, the recent market price per share of Common Stock used throughout this prospectus as an assumed combined public offering price may not be indicative of the final offering price.

We are an “emerging growth company” and a “smaller reporting company” as defined under federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and may elect to comply with reduced public company reporting requirements in future filings. See “Prospectus Summary––Implications of Being an Emerging Growth Company and a Smaller Reporting Company.”

Investing in our securities involves a high degree of risk. See the section entitled“ Risk Factors” beginning on page 7 of this prospectus for a discussion of risks that should be considered in connection with an investment in our securities.

|                                    |     |   | Per                        
 Share and accompanying May 
 2025                       
 Warrant                    |     |   | Per                  
 Pre-Funded Warrant   
 and accompanying May 
 2025                 
 Warrant              |     |   | Total |
|:-----------------------------------|:----|:--|:---------------------------|:----|:--|:---------------------|:----|:--|:------|
| Public offering price              |     | $ |                            |